0.009 (10.0%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/A
Telephone
N/A
Address
Description
Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. It focuses on understanding and defining the mechanisms that regulate pressure in the brain and aims to repurpose and reformulate an already approved drug, Exenatide. The company was founded by Jason Loveridge and Alexandra J. Sinclair on March 8, 2019 and is headquartered in Subiaco, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.06 - 0.1
Trade Value (12mth)
AU$422.00
1 week
23.75%
1 month
41.43%
YTD
41.43%
1 year
26.92%
All time high
0.52
EPS 3 yr Growth
-28.30%
EBITDA Margin
N/A
Operating Cashflow
-$2m
Free Cash Flow Return
-18.20%
ROIC
-12.20%
Interest Coverage
N/A
Quick Ratio
14.20
Shares on Issue (Fully Dilluted)
75m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.01
| Date | Announcements |
|---|---|
|
08 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
20 February 25 |
Details of Company Address
×
Details of Company Address |
|
07 February 25 |
Appendix 4D and Half Year Report
×
Appendix 4D and Half Year Report |
|
22 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
20 January 25 |
Invex Receives $0.22m R&D Tax Rebate from UK Government
×
Invex Receives $0.22m R&D Tax Rebate from UK Government |
|
16 December 24 |
Improved Neuronal Cell Survival in 3D Model of Alzheimer's
×
Improved Neuronal Cell Survival in 3D Model of Alzheimer's |
|
26 November 24 |
Results of Meeting
×
Results of Meeting |
|
26 November 24 |
Chair's Address to Shareholders
×
Chair's Address to Shareholders |
|
17 October 24 |
Addendum to Notice of Annual General Meeting
×
Addendum to Notice of Annual General Meeting |
|
14 October 24 |
Letter to Shareholders AGM
×
Letter to Shareholders AGM |
|
14 October 24 |
Notice of Annual General Meeting
×
Notice of Annual General Meeting |
|
08 October 24 |
Quarterly Activities Report and Appendix 4C
×
Quarterly Activities Report and Appendix 4C |
|
23 September 24 |
Date of AGM and Closing Date for Director Nominations
×
Date of AGM and Closing Date for Director Nominations |
|
22 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
|
22 August 24 |
Appendix 4E and Annual Report to shareholders
×
Appendix 4E and Annual Report to shareholders |
|
30 July 24 |
Change in substantial holding
×
Change in substantial holding |
|
23 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
01 July 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
|
26 June 24 |
Notification of cessation of securities - IXC
×
Notification of cessation of securities - IXC |
|
21 June 24 |
Invex receives R&D Tax Rebate
×
Invex receives R&D Tax Rebate |
|
18 June 24 |
Resignation of Dr Megan Baldwin
×
Resignation of Dr Megan Baldwin |
|
19 April 24 |
Details of Auditor Appointment/Resignation
×
Details of Auditor Appointment/Resignation |
|
12 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
09 April 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
|
08 April 24 |
Notification of cessation of securities - IXC
×
Notification of cessation of securities - IXC |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
